|
 |
Kauppanimi |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Eberelbin |
Iran |
|
Eunexon |
Marokko |
|
Eurovinorelbin |
Saksa |
|
Navelbin |
Unkari |
|
Navelbine |
Argentiina, Australia, Belgia, Chile, Egypti, Espanja, Intia, Iran, Irlanti, Islanti, Iso-Britannia, Italia, Itävalta, Kolumbia, Kreikka, Luxemburg, Malesia, Marokko, Meksiko, New Zealand, Norja, Portugali, Puola, Ranska, Romania, Ruotsi, Saksa, Saudi-Arabia, Suomi, Sveitsi, Tanska, Tunisia, Turkki, Yhdistyneet arabiemiirikunnat, Yhdysvallat |
|
Navildez |
Meksiko |
|
Navin |
Saksa |
|
Navirel |
Norja, Ruotsi, Saksa |
|
Okabine |
Marokko |
|
Relbinalur |
Ruotsi |
|
Renovel |
Turkki |
|
Setroxin |
Meksiko |
|
Sulcoline |
Argentiina |
|
Tarckorel |
Marokko, Meksiko |
|
Vieby |
Meksiko |
|
Viessia |
Kolumbia, Meksiko, Venezuela |
|
Vilne |
Argentiina, Ecuador, Marokko |
|
Vinarine |
Argentiina, Marokko, Venezuela |
|
Vinelbine |
Malesia |
|
Vinilex |
Meksiko |
|
Vinkebir |
Argentiina, Marokko |
|
Vinobina |
Kolumbia |
|
Vinobur |
Ruotsi |
|
Vinolbin |
Saksa |
|
Vinorel |
Argentiina, Marokko |
|
Vinorelbin |
Belgia, Ecuador, Islanti, Itävalta, Norja, Romania, Ruotsi, Saksa, Sveitsi |
|
Vinorelbina |
Ecuador, Espanja, Kolumbia, Marokko, Meksiko, Romania |
|
Vinorelbine |
Argentiina, Belgia, Iran, Iso-Britannia, Kanada, New Zealand, Sveitsi, Yhdysvallat |
|
Vinorgen |
Chile, Marokko |
|
Zinavin |
Kolumbia |
|
|
 |
 |
Viitteet : Vinorelbine tartrate |
|
|
Tyyppi |
Julkaisu |
| 84 |
Lehti |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 144 |
Lehti |
Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285. |
| 182 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 251 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 307 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 905 |
Lehti |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1070 |
Lehti |
Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891. |
| 1413 |
Lehti |
Lieu CL, Chin A, Gill MA.
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Int J Pharm Compound 1999 ; 3: 67-68. |
| 1423 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1501 |
Lehti |
Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121. |
| 1520 |
Laboratorio |
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001 |
| 1625 |
Lehti |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Lehti |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 2260 |
Laboratorio |
Stability of vinorelbin "Ebewe" infusion solutions.
Ebewe Pharma 2007 |
| 3128 |
Laboratorio |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3474 |
Laboratorio |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3595 |
Laboratorio |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3641 |
Laboratorio |
Vinorelbine (Navelbine®) - Summary of Product Characteristics
Pierre Fabre 2011 |
| 3644 |
Laboratorio |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3838 |
Laboratorio |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 4471 |
Laboratorio |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
|
|
